Maxime Dely on The vital Role of Plasma in Immune-Deficient Patients
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”Immunoglobulins: when plasma becomes a vital treatment for immune-deficient patients
Intravenous and subcutaneous immunoglobulins (IVIg, SCIg), produced exclusively from plasma donations, are life-saving medicines.
They replace or support the immune system in a wide range of conditions.
Main indications
- Primary immunodeficiencies (rare and severe congenital disorders)
- Secondary immunodeficiencies (after transplantation, chemotherapy, uncontrolled HIV, etc.)
- Autoimmune and neurological diseases (Guillain-Barré syndrome, myasthenia gravis, Kawasaki disease, immune thrombocytopenia, and more)
Worldwide
Today, millions of patients rely on immunoglobulin therapy every year.
Currently, the global demand is growing steadily (+5–7% annually), driven by broader indications and aging populations.
Unfortunately, there is no synthetic or recombinant alternative today — plasma is the only source.
Immunoglobulins are not only life-saving but also critical for maintaining quality of life in chronic patients.
Behind every infusion of immunoglobulins, there are thousands of plasma donations, transformed into precious medicines.
How can we raise more awareness about the growing importance of plasma-derived immunoglobulins, as global demand keeps rising?”
Stay updated on all scientific advances in the field of transfusion medicine with Hemostasis Today.
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability